While not used to guide treatment, ESR and CRP typically normalize within two to four weeks after initiating therapy. 2,4 Minor increases in ESR can occur during the prednisone taper, but this does ...

Glucocorticoids are commonly used to treat giant cell arteritis but these drugs come with serious adverse effects when taken ...

Giant cell arteritis is the most common form of systemic vasculitis in people over the age of 50. It affects large‐ and medium‐sized blood vessels, particularly in the head—although not exclusively.

Secukinumab (Cosentyx) showed promise as a steroid-sparing agent in giant cell arteritis, a researcher reported here. In a phase II trial that enrolled 52 patients, 70.1% (95% CI 51.6-84.9) of those ...

Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in ...

Objective To evaluate the diagnostic pathway of patients affected by large vessel vasculitis (LVV) and to determine factors ...

A substantial proportion of patients with apparently isolated giant cell arteritis may also have subclinical polymyalgia ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

Exposure to environmental particulate matter ≤ 10 μm in diameter (PM 10) is associated with an increased risk for giant cell arteritis, particularly in older individuals aged ≥ 70 years and those with ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

Please provide your email address to receive an email when new articles are posted on . Although it is known that the selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq, AbbVie) blocks the ...

The final 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Credit: Annals of the Rheumatic Diseases (2022). DOI: 10.1136/ard-2022-223480 Giant cell ...